Development of a primary microglia screening assay and its use to characterize inhibition of system xc - by erastin and its analogs

Mariana Figuera-Losada, Ajit G. Thomas, Marigo Stathis, Brent R. Stockwell, Camilo Rojas, Barbara S. Slusher

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The inflammatory response in the central nervous system involves activated microglia. Under normal conditions they remove damaged neurons by phagocytosis. On the other hand, neurodegenerative diseases are thought to involve chronic microglia activation resulting in release of excess glutamate, proinflammatory cytokines and reactive oxygen species, leading to neuronal death. System xC - cystine/glutamate antiporter (SXC), a sodium independent heterodimeric transporter found in microglia and astrocytes in the CNS, imports cystine into the cell and exports glutamate. SXC has been shown to be upregulated in neurodegenerative diseases including multiple sclerosis, ALS, neuroAIDS Parkinson's disease and Alzheimer's disease. Consequently, SXC inhibitors could be of use in the treatment of diseases characterized by neuroinflammation and glutamate excitotoxicity. We report on the optimization of a primary microglia-based assay to screen for SXC inhibitors. Rat primary microglia were activated using lipopolysaccharides (LPS) and glutamate release and cystine uptake were monitored by fluorescence and radioactivity respectively. LPS-induced glutamate release increased with increasing cell density, time of incubation and LPS concentration. Conditions to screen for SXC inhibitors were optimized in 96-well format and subsequently used to evaluate SXC inhibitors. Known SXC inhibitors sulfasalazine, S-4CPG and erastin blocked glutamate release and cystine uptake while R-4CPG, the inactive enantiomer of S-4CPG, failed to inhibit glutamate release or cystine transport. In addition, several erastin analogs were evaluated using primary microglia and found to have EC50 values in agreement with previous studies using established cell lines.

Original languageEnglish (US)
Pages (from-to)266-272
Number of pages7
JournalBiochemistry and Biophysics Reports
Volume9
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Microglia
Cystine
Glutamic Acid
Assays
Screening
Antiporters
Neurodegenerative diseases
Lipopolysaccharides
erastin
Inhibition (Psychology)
Neurodegenerative Diseases
Sulfasalazine
Enantiomers
Radioactivity
Neurology
Phagocytosis
Astrocytes
Neurons
Multiple Sclerosis
Parkinson Disease

Keywords

  • (S)-4-CPG
  • CCF-STTG-1 cells
  • Erastin
  • Primary microglia
  • Sulfasalazine
  • System x

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Development of a primary microglia screening assay and its use to characterize inhibition of system xc - by erastin and its analogs. / Figuera-Losada, Mariana; Thomas, Ajit G.; Stathis, Marigo; Stockwell, Brent R.; Rojas, Camilo; Slusher, Barbara S.

In: Biochemistry and Biophysics Reports, Vol. 9, 01.03.2017, p. 266-272.

Research output: Contribution to journalArticle

Figuera-Losada, Mariana ; Thomas, Ajit G. ; Stathis, Marigo ; Stockwell, Brent R. ; Rojas, Camilo ; Slusher, Barbara S. / Development of a primary microglia screening assay and its use to characterize inhibition of system xc - by erastin and its analogs. In: Biochemistry and Biophysics Reports. 2017 ; Vol. 9. pp. 266-272.
@article{f2f106a3ed784e008a4acb32bd9cae01,
title = "Development of a primary microglia screening assay and its use to characterize inhibition of system xc - by erastin and its analogs",
abstract = "The inflammatory response in the central nervous system involves activated microglia. Under normal conditions they remove damaged neurons by phagocytosis. On the other hand, neurodegenerative diseases are thought to involve chronic microglia activation resulting in release of excess glutamate, proinflammatory cytokines and reactive oxygen species, leading to neuronal death. System xC - cystine/glutamate antiporter (SXC), a sodium independent heterodimeric transporter found in microglia and astrocytes in the CNS, imports cystine into the cell and exports glutamate. SXC has been shown to be upregulated in neurodegenerative diseases including multiple sclerosis, ALS, neuroAIDS Parkinson's disease and Alzheimer's disease. Consequently, SXC inhibitors could be of use in the treatment of diseases characterized by neuroinflammation and glutamate excitotoxicity. We report on the optimization of a primary microglia-based assay to screen for SXC inhibitors. Rat primary microglia were activated using lipopolysaccharides (LPS) and glutamate release and cystine uptake were monitored by fluorescence and radioactivity respectively. LPS-induced glutamate release increased with increasing cell density, time of incubation and LPS concentration. Conditions to screen for SXC inhibitors were optimized in 96-well format and subsequently used to evaluate SXC inhibitors. Known SXC inhibitors sulfasalazine, S-4CPG and erastin blocked glutamate release and cystine uptake while R-4CPG, the inactive enantiomer of S-4CPG, failed to inhibit glutamate release or cystine transport. In addition, several erastin analogs were evaluated using primary microglia and found to have EC50 values in agreement with previous studies using established cell lines.",
keywords = "(S)-4-CPG, CCF-STTG-1 cells, Erastin, Primary microglia, Sulfasalazine, System x",
author = "Mariana Figuera-Losada and Thomas, {Ajit G.} and Marigo Stathis and Stockwell, {Brent R.} and Camilo Rojas and Slusher, {Barbara S.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.bbrep.2016.12.009",
language = "English (US)",
volume = "9",
pages = "266--272",
journal = "Biochemistry and Biophysics Reports",
issn = "2405-5808",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Development of a primary microglia screening assay and its use to characterize inhibition of system xc - by erastin and its analogs

AU - Figuera-Losada, Mariana

AU - Thomas, Ajit G.

AU - Stathis, Marigo

AU - Stockwell, Brent R.

AU - Rojas, Camilo

AU - Slusher, Barbara S.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The inflammatory response in the central nervous system involves activated microglia. Under normal conditions they remove damaged neurons by phagocytosis. On the other hand, neurodegenerative diseases are thought to involve chronic microglia activation resulting in release of excess glutamate, proinflammatory cytokines and reactive oxygen species, leading to neuronal death. System xC - cystine/glutamate antiporter (SXC), a sodium independent heterodimeric transporter found in microglia and astrocytes in the CNS, imports cystine into the cell and exports glutamate. SXC has been shown to be upregulated in neurodegenerative diseases including multiple sclerosis, ALS, neuroAIDS Parkinson's disease and Alzheimer's disease. Consequently, SXC inhibitors could be of use in the treatment of diseases characterized by neuroinflammation and glutamate excitotoxicity. We report on the optimization of a primary microglia-based assay to screen for SXC inhibitors. Rat primary microglia were activated using lipopolysaccharides (LPS) and glutamate release and cystine uptake were monitored by fluorescence and radioactivity respectively. LPS-induced glutamate release increased with increasing cell density, time of incubation and LPS concentration. Conditions to screen for SXC inhibitors were optimized in 96-well format and subsequently used to evaluate SXC inhibitors. Known SXC inhibitors sulfasalazine, S-4CPG and erastin blocked glutamate release and cystine uptake while R-4CPG, the inactive enantiomer of S-4CPG, failed to inhibit glutamate release or cystine transport. In addition, several erastin analogs were evaluated using primary microglia and found to have EC50 values in agreement with previous studies using established cell lines.

AB - The inflammatory response in the central nervous system involves activated microglia. Under normal conditions they remove damaged neurons by phagocytosis. On the other hand, neurodegenerative diseases are thought to involve chronic microglia activation resulting in release of excess glutamate, proinflammatory cytokines and reactive oxygen species, leading to neuronal death. System xC - cystine/glutamate antiporter (SXC), a sodium independent heterodimeric transporter found in microglia and astrocytes in the CNS, imports cystine into the cell and exports glutamate. SXC has been shown to be upregulated in neurodegenerative diseases including multiple sclerosis, ALS, neuroAIDS Parkinson's disease and Alzheimer's disease. Consequently, SXC inhibitors could be of use in the treatment of diseases characterized by neuroinflammation and glutamate excitotoxicity. We report on the optimization of a primary microglia-based assay to screen for SXC inhibitors. Rat primary microglia were activated using lipopolysaccharides (LPS) and glutamate release and cystine uptake were monitored by fluorescence and radioactivity respectively. LPS-induced glutamate release increased with increasing cell density, time of incubation and LPS concentration. Conditions to screen for SXC inhibitors were optimized in 96-well format and subsequently used to evaluate SXC inhibitors. Known SXC inhibitors sulfasalazine, S-4CPG and erastin blocked glutamate release and cystine uptake while R-4CPG, the inactive enantiomer of S-4CPG, failed to inhibit glutamate release or cystine transport. In addition, several erastin analogs were evaluated using primary microglia and found to have EC50 values in agreement with previous studies using established cell lines.

KW - (S)-4-CPG

KW - CCF-STTG-1 cells

KW - Erastin

KW - Primary microglia

KW - Sulfasalazine

KW - System x

UR - http://www.scopus.com/inward/record.url?scp=85010424690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010424690&partnerID=8YFLogxK

U2 - 10.1016/j.bbrep.2016.12.009

DO - 10.1016/j.bbrep.2016.12.009

M3 - Article

VL - 9

SP - 266

EP - 272

JO - Biochemistry and Biophysics Reports

JF - Biochemistry and Biophysics Reports

SN - 2405-5808

ER -